Strategic acquisition of diversion detection capabilities strengthens Company’s commitment to supporting enhanced pharmacy oversight, clinician and patient safety, and compliance
Fort Worth, TX, -- October 27, 2025 —Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced it has acquired ANiGENT, LLC, a software company focused on delivering drug diversion detection through a proprietary intelligence platform. The acquisition is expected to add important drug diversion surveillance and monitoring capabilities to Omnicell’s portfolio of outcomes-centric medication management solutions, that are designed to enable compliance and foster a culture of transparency.
The annual cost impact of prescription drug diversion is estimated at $72.5 billion.1 According to the American Society of Health-System Pharmacists, controlled substances diversion in health systems can lead to serious patient safety issues, harm to the diverter, and significant liability risk to the organization.
Designed by clinicians for clinicians and built to address the real-world challenges of diversion monitoring, these new capabilities are intended to help healthcare organizations of all sizes to proactively detect, investigate, and prevent diversion through comprehensive tracking of high-risk medication inventory and staff access across care locations, technologies, and workflows.
“We recognize the potentially serious impact of drug diversion to operational efficiency and patient care,” said Nish Parekh, senior vice president and chief product officer at Omnicell. “We believe the addition of these new capabilities to Omnicell’s portfolio will provide our customers the visibility and actionable insights they need to support enhanced patient safety and compliance.”
Additional capabilities anticipated to be available to customers in the first half of 2026 include:
- Benchmarking: Real-time, executive view that is meant to help visualize facility-specific KPIs, pinpoint potential medication risks, and help support tracking of compliance improvements over time.
- Centralized Case Management: Full case management ecosystem provides a “watch list” and action board designed to support investigations, so evidence, communications, and steps may be documented in one accessible place.
- Waste Assay and Reconciliation: Supports monitoring of waste discrepancies and waste assay results, which may be a key indicator of drug diversion.
Learn more about Omnicell’s full portfolio of medication management solutions at omnicell.com.
About ANiGENT
ANiGENT was established in 2019 to deliver a comprehensive, patent-pending drug diversion detection platform: Medication Administration & Analysis Program (MAAP Analytics®). Built by clinicians for clinicians and backed by over 10 years of refinements in a clinical setting, MAAP Analytics leverages human intelligence enabled by machine learning to track all users, all medications, in all locations and identify the root cause of discrepancies in minutes.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. This press release may also include the trademarks and service marks of other companies. Such trademarks and service marks are the marks of their respective owners.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s expectations regarding the outcome of the acquisition, the expected benefits of the acquisition of the ANiGENT, LLC business, including the impact of the acquisition on Omnicell’s products and services, the capabilities and benefits of the products and services of the ANiGENT, LLC business and related objectives (and any implied financial impact). Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, difficulties encountered or delays in integrating the acquired business, including those related to technologies, personnel and operations; market acceptance of the acquired capabilities and resulting products and services; Omnicell’s inability to realize value from the acquisition, including product and service innovations; unfavorable general economic and market conditions, and other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Readers are encouraged to review this press release in conjunction with our most recent Annual Report on Form 10-K and our other reports filed with or furnished to the SEC. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
1 https://www.pharmacytimes.com/view/the-high-cost-of-drug-diversion